دورية أكاديمية
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease.
| العنوان: | Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease. |
|---|---|
| المؤلفون: | Sanber K; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA., Ye K; Johns Hopkins University School of Medicine, Baltimore, MD, USA., Tsai HL; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA., Newman M; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital Department of Pharmacy, Baltimore, MD, USA., Webster JA; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA., Gojo I; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA., Ghiaur G; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA., Prince GT; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA., Gondek LP; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA., Smith BD; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA., Levis MJ; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA., DeZern AE; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA., Ambinder AJ; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA., Dalton WB; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA., Jain T; Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA. |
| المصدر: | Leukemia & lymphoma [Leuk Lymphoma] 2023 Apr; Vol. 64 (4), pp. 846-855. Date of Electronic Publication: 2023 Feb 06. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: [Philadelphia, PA] : Taylor & Francis Original Publication: Chur ; New York : London, UK : Harwood Academic Publishers ; Distributed by STBS, 1989- |
| مواضيع طبية MeSH: | Myeloproliferative Disorders*/diagnosis , Myeloproliferative Disorders*/drug therapy , Myeloproliferative Disorders*/genetics , Leukemia, Myeloid, Acute*/diagnosis , Leukemia, Myeloid, Acute*/drug therapy , Leukemia, Myeloid, Acute*/genetics, Humans ; Retrospective Studies ; Bridged Bicyclo Compounds, Heterocyclic/adverse effects ; Sulfonamides ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Azacitidine/therapeutic use |
| مستخلص: | The combination of venetoclax and hypomethylating agent (HMA/venetoclax) has emerged as a treatment option for patients with de novo acute myeloid leukemia (AML) who are unfit to receive intensive chemotherapy. In this single-center retrospective study, we evaluated clinical outcomes following treatment with HMA/venetoclax in 35 patients with advanced myeloproliferative neoplasms, myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes or AML with extramedullary disease. The composite complete remission (CR) rate (including confirmed/presumed complete cytogenetic response, acute leukemia response-complete, CR and CR with incomplete hematologic recovery) was 42.9% with median overall survival (OS) of 9.7 months. Complex karyotype was associated with inferior median OS (3.7 versus 12.2 months; p = 0.0002) and composite CR rate (22% versus 50.0%; p = 0.2444). Although SRSF2 mutations were associated with higher composite CR rate (80.0% versus 28.0%; p = 0.0082), this was not associated with longer median OS (10.9 versus 8.0 months; p = 0.2269). Future studies should include these patient subgroups. |
| التعليقات: | Comment in: Leuk Lymphoma. 2023 Apr;64(4):757-760. (PMID: 37037568) |
| فهرسة مساهمة: | Keywords: Myeloproliferative neoplasm; acute myeloid leukemia; azacitidine; decitabine; extramedullary disease; hypomethylating agents; myelodysplastic/myeloproliferative neoplasm; venetoclax |
| المشرفين على المادة: | N54AIC43PW (venetoclax) 0 (Bridged Bicyclo Compounds, Heterocyclic) 0 (Sulfonamides) M801H13NRU (Azacitidine) |
| تواريخ الأحداث: | Date Created: 20230206 Date Completed: 20230418 Latest Revision: 20230523 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1080/10428194.2023.2173523 |
| PMID: | 36744656 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1029-2403 |
|---|---|
| DOI: | 10.1080/10428194.2023.2173523 |